Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors
Santo Previti, Roberta Ettari, Elsa Calcaterra, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115021-115021
Open Access | Times Cited: 19

Showing 19 citing articles:

Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li, Yongcheng Song
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115772-115772
Open Access | Times Cited: 51
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1339-1339
Open Access | Times Cited: 22
Revisiting the potential of natural antimicrobial peptides against emerging respiratory viral disease: a review
Neelakanta Sarvashiva Kiran, Sudarshan Singh, Chandrashekar Yashaswini, et al.
3 Biotech (2025) Vol. 15, Iss. 2
Closed Access
Design, synthesis and biological activity of peptidyl β-nitrostyrenes as cysteine protease inhibitors against Leishmania donovani
Sweta Sharma, Mirza Beg, Insha Latief, et al.
RSC Advances (2025) Vol. 15, Iss. 8, pp. 5703-5719
Open Access
Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19
Fu-Mao Zhang, Ting Huang, Feng Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115721-115721
Closed Access | Times Cited: 12
Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CLpro inhibitors
Feng Wang, Donglan Liu, Dingding Gao, et al.
International Journal of Biological Macromolecules (2024) Vol. 264, pp. 130377-130377
Closed Access | Times Cited: 4
Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions
Ahmed M. Shawky, Faisal A. Almalki, Hayat Ali Alzahrani, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116704-116704
Closed Access | Times Cited: 4
Recent Advances on SARS-CoV-2 Mpro Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
(2023)
Open Access | Times Cited: 11
AI-driven covalent drug design strategies targeting main protease (m pro ) against SARS-CoV-2: structural insights and molecular mechanisms
Mohammad Hossein Haghir Ebrahim Abadi, Abdulrahman Ghasemlou, Fatemeh Bayani, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-29
Closed Access | Times Cited: 3
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2
Larysa V. Yevsieieva, Kateryna Lohachova, Alexander Kyrychenko, et al.
RSC Advances (2023) Vol. 13, Iss. 50, pp. 35500-35524
Open Access | Times Cited: 9
Critical assessment of popular biomolecular force fields for molecular dynamics simulations of folding and enzymatic activity of main protease of coronavirus SARS-CoV-2
Kateryna Lohachova, Alexander Kyrychenko, Oleg N. Kalugin
Biophysical Chemistry (2024) Vol. 311, pp. 107258-107258
Closed Access | Times Cited: 2
Computational Design, Synthesis, and Biophysical Evaluation of β-Amido Boronic Acids as SARS-CoV-2 Mpro Inhibitors
Enrico Mario Alessandro Fassi, Marco Manenti, Andrea Citarella, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2356-2356
Open Access | Times Cited: 6
Identification of Dual Inhibitors Targeting Main Protease (Mpro) and Cathepsin L as Potential Anti-SARS-CoV-2 Agents
Santo Previti, Roberta Ettari, Elsa Calcaterra, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 5, pp. 602-609
Closed Access | Times Cited: 1
Differential specificity of SARS‐CoV‐2 main protease variants on peptide versus protein‐based substrates
Fernanda dos Reis Rocho, Scott J. Snipas, Anwar Shamim, et al.
FEBS Journal (2023) Vol. 291, Iss. 1, pp. 61-69
Open Access | Times Cited: 2
Rhodesain Inhibitors on the Edge of Reversibility-Irreversibility
Florenci V. González, Laura Agost-Beltrán, Collin Zimmer, et al.
(2024)
Closed Access
Rhodesain inhibitors on the edge of reversibility-irreversibility
Laura Agost-Beltrán, Collin Zimmer, Hans Joachim Räder, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107830-107830
Open Access
Dipeptide Nitrile CD34 with Curcumin: A New Improved Combination Strategy to Synergistically Inhibit Rhodesain of Trypanosoma brucei rhodesiense
Carla Di Chio, Santo Previti, Noemi Totaro, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8477-8477
Open Access | Times Cited: 1
Recent Efforts in Identification of Privileged Scaffolds as Antiviral Agents
Yogesh Yadav, Kavita Singh, Sunil Sharma, et al.
Chemistry & Biodiversity (2023) Vol. 20, Iss. 10
Closed Access
Investigando a especificidade e inibição da principal protease do SARS-CoV-2 e suas variantes
Fernanda dos Reis Rocho
(2023)
Open Access
Page 1

Scroll to top